Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 10,300 shares, a decrease of 86.7% from the December 15th total of 77,600 shares. Based on an average trading volume of 153,100 shares, the days-to-cover ratio is currently 0.1 days.

Bioxytran Price Performance

Shares of BIXT traded down $0.00 during mid-day trading on Monday, hitting $0.10. The company’s stock had a trading volume of 136,712 shares, compared to its average volume of 394,173. The firm has a 50-day moving average price of $0.09 and a 200 day moving average price of $0.10. Bioxytran has a fifty-two week low of $0.06 and a fifty-two week high of $0.15. The stock has a market capitalization of $8.24 million, a price-to-earnings ratio of -9.50 and a beta of -0.55.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.